Albany Molecular Research (AMRI) Misses Q1 EPS by 14c

May 10, 2016 7:38 AM EDT

Albany Molecular Research (NASDAQ: AMRI) reported Q1 EPS of $0.07, $0.14 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $102.8 million versus the consensus estimate of $107.2 million.

Albany Molecular Research reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings